Interius Biotherapeutics is developing cell and gene therapies to treat cancer. Chimeric antigen receptor (CAR) T-cell therapies involve removing and engineering patient T cells to recognise cancerous cells. Interius is instead focused on engineering T cells directly in vivo, bypassing the need for ex vivo manipulations and the potentially toxic pre-conditioning chemotherapy. This approach will involve development of next generation delivery technology so that the right cells are given the right payload for the right disease. Interius is in preclinical stages currently investigating viral-mediated delivery modalities to quantitate strength and purity and is also developing applications beyond immuno-oncology.